




PHARMACEUTICAL 2018

Achillion Pharmaceuticals INC Rank 16 of 332

The relative strengths and weaknesses of Achillion Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Achillion Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 178% points. The greatest weakness of Achillion Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 406%, being 154% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	303,938
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,884
Liabilities, Non-Current	131
Other Assets	30,859
Other Compr. Net Income	-540
Other Expenses	50
Other Liabilities	83
Other Net Income	4,390
Other Revenues	0
Property and Equipment	2,816
Research and Development	65,052
Selling, General and Administrative Expense	24,524

Output Variable	Value in 1000 USD
Assets	337,613
Liabilities	13,098
Expenses	89,626
Revenues	0
Stockholders Equity	324,515
Net Income	-85,236
Comprehensive Net Income	-85,506
BaseVar	222,634
ECR before LimitedLiability	355%
Economic Capital Ratio	406%